Genmab A/S (LON:0MGB)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 16.81B +13.1% |
| Revenue (ttm) | 3.11B +22.3% |
| Net Income | 593.92M -37.9% |
| EPS | 9.53 -36.8% |
| Shares Out | n/a |
| PE Ratio | 28.24 |
| Forward PE | 23.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,860 |
| Open | 2,414.00 |
| Previous Close | 2,470.00 |
| Day's Range | 2,410.00 - 2,491.00 |
| 52-Week Range | 1,514.50 - 2,604.00 |
| Beta | 0.65 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial numbers in USD Financial StatementsNews
Genmab Reports $4.24 Billion In Third-Quarter DARZELEX Sales, Up Year Over Year
(RTTNews) - Genmab (GMAB) announced that worldwide net sales of DARZALEX (daratumumab), as reported by partner Johnson & Johnson (JNJ), totaled $4.24 billion during the third quarter of 2026, up from ...
Genmab reports Q3 net sales of Darzalex $4.24B
Genmab (GMAB) announced that worldwide net trade sales of Darzalex – daratumumab -, including sales of the subcutaneous product sold under the tradename Darzalex Faspro in the U.S., as reported…
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
Company Announcement Net sales of DARZALEX ® in the third quarter of 2026 totaled USD 4,239 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen B...
Genmab (CPH:GEN) -- Pipeline Progress and Market Resilience | Baird Funds Q3 2026
Genmab (CPH:GEN) -- Pipeline Progress and Market Resilience | Baird Funds Q3 2026
Genmab To Issue Restricted Stock Units To Board Members As Renumeration
(RTTNews) - Genmab A/S (GMAB), a biotechnology company, on Wednesday reported the results of an Extraordinary General Meeting to determine a share-based renumeration for the company's Board of Directo...
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members
Company Announcement COPENHAGEN, Denmark; October 7, 2026 – Genmab A/S (Nasdaq: GMAB) Today, Genmab A/S held an Extraordinary General Meeting.At the Extraordinary General Meeting the proposal from ...
Genmab price target raised to $45 from $40 at Truist
Truist raised the firm’s price target on Genmab (GMAB) to $45 from $40 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Genmab price target raised to $58 from $54 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on Genmab (GMAB) to $58 from $54 and keeps a Buy rating on the shares, which remain a Top Pick of…
Genmab price target raised to $50 from $40 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $50 from $40 and keeps a Buy rating on the shares. The company announced positive results from the Phase…
Genmab Slides: FY 2026
Genmab has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 7, 2026.
Genmab price target raised to DKK 2,850 from DKK 2,500 at BofA
BofA analyst Charlie Haywood raised the firm’s price target on Genmab (GMAB) to DKK 2,850 from DKK 2,500 and keeps a Buy rating on the shares after the company announced…
Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug
The Danish company said the Epkinly drug helped extend the time patients with a common type of lymphoma lived.
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?
Genmab (GMAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength dow...
AbbVie, Genmab's Epcoritamab Plus R-CHOP Improves PFS & Cuts Progression Risk In Lymphoma
(RTTNews) - AbbVie (ABBV) and Genmab (GMAB) reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large B-...
AbbVie, Genmab's Epcoritamab Plus R-CHOP Improves PFS In DLBCL
(RTTNews) - AbbVie (ABBV) and Genmab (GMAB) reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large B-...
Genmab (GMAB) and AbbVie Phase 3 Trial Shows Epkinly Boosts DLBCL Treatment Outcomes
Genmab (GMAB) and AbbVie Phase 3 Trial Shows Epkinly Boosts DLBCL Treatment Outcomes
AbbVie Partner Flies Sky-High On News For Its $3 Billion Cancer Contender
The addition of Genmab's Epkinly to a standard cocktail of drugs helped lymphoma patients live longer before worsening. Genmab stock rocketed.
Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study
Genmab A/S (GMAB) and AbbVie (ABBV) announced “positive” topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody ad...
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS)...
Genmab A/S: Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (...
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating ...
Genmab price target raised to $54 from $45 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on Genmab (GMAB) to $54 from $45 and keeps a Buy rating on the shares. The stock remains the analyst’s top…
Genmab (GMAB) Reports Encouraging Phase 1/2 RAINFOL-01 Results in Platinum-Resistant Ovarian Cancer
Genmab (GMAB) Reports Encouraging Phase 1/2 RAINFOL-01 Results in Platinum-Resistant Ovarian Cancer
Genmab announces Rina-S Phase 2 RAINFOL-1 trial results
Genmab (GMAB) announced results from Part C of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan demonstrated that among 109 treated patients with platinum-resistant ovarian cancer, PROC,...
Genmab Reports Positive Phase 1/2 Data For Rina-S In Resistant Ovarian Cancer
(RTTNews) - Genmab A/S (GMAB) reported positive results from Part C of the Phase 1/2 RAINFOL-01 trial evaluating investigational antibody-drug conjugate rinatabart sesutecan (Rina-S) in patients with ...